
-
Trevena Inc OTC Markets OTCPK:TRVN Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Location: 955 Chesterbrook Boulevard, Chesterbrook, PA, 19087, United States | Website: https://www.trevena.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
25.18M
Cash
13.46M
Avg Qtr Burn
-6.773M
Short % of Float
7.30%
Insider Ownership
0.49%
Institutional Own.
9.99%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Approved Quarterly sales | ||
TRV250 (Delta receptor agonist) Details Migraines | Phase 2 Initiation | |
TRV045 (S1P receptor) Details Epilepsy, Central nervous system illness, Pain | Phase 1 Data readout | |
TRV734 (Mu receptor agonist) Details Opioid use disorder | Failed Discontinued | |
TRV027 (AT1 receptor selective agonist) Details Acute respiratory distress syndrome, Infectious disease, COVID-19 | Failed Discontinued |